Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Liabilities and Shareholders Equity (2023 - 2026)

Xilio Therapeutics' Liabilities and Shareholders Equity history spans 4 years, with the latest figure at $163.5 million for Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 57.63% to $163.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $585.7 million, a 72.6% increase, with the full-year FY2025 number at $154.7 million, up 117.64% from a year prior.
  • Liabilities and Shareholders Equity hit $163.5 million in Q1 2026 for Xilio Therapeutics, up from $154.7 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for XLO hit a ceiling of $163.5 million in Q1 2026 and a floor of $60.9 million in Q4 2023.
  • Historically, Liabilities and Shareholders Equity has averaged $106.9 million across 4 years, with a median of $96.8 million in 2024.
  • Biggest five-year swings in Liabilities and Shareholders Equity: increased 16.66% in 2024 and later skyrocketed 117.64% in 2025.
  • Tracing XLO's Liabilities and Shareholders Equity over 4 years: stood at $60.9 million in 2023, then rose by 16.66% to $71.1 million in 2024, then skyrocketed by 117.64% to $154.7 million in 2025, then grew by 5.69% to $163.5 million in 2026.
  • Business Quant data shows Liabilities and Shareholders Equity for XLO at $163.5 million in Q1 2026, $154.7 million in Q4 2025, and $133.7 million in Q3 2025.